Neoadjuvant GOLP Prolongs EFS Among Patients with Resectable High-Risk Intrahepatic Cholangiocarcinoma / ESMO

esmo - Findings from the ZSAB-neoGOLP study

#healthcare #pharmaceuticals #biotech #drugdevelopment #oncology #cancerresearch #clinicaltrials

Nieves Martinez Lago: Time Toxicity in First-Line BTC Treatment

6 hrs / oncodaily

Neoadjuvant GOLP Prolongs EFS Among Patients with Resectable High-Risk Intrahepatic Cholangiocarcinoma

16 hrs / esmo

Neoadjuvant GOLP in Resectable High-Risk Intrahepatic Cholangiocarcinoma: ZSAB-neoGOLP Trial

5 days / oncodaily

Monday, March 16, 2026, 3:21 am / permalink 20797 / 3 stories in 15 hrs

Related Stories

Related Tags

Healthcare

HIMSS 2026 pushes real‑time data, cloud and interoperability playbook (14 hrs)

Vitamin D trial shows reduced long‑COVID risk but no severity benefit (17 hrs)

Atezolizumab added to chemoradiation fails to improve limited‑stage SCLC survival (18 hrs)

more #healthcare

Pharmaceuticals

Atezolizumab added to chemoradiation fails to improve limited‑stage SCLC survival (18 hrs)

FDA approves leucovorin for rare folate disorder despite autism hype (30 hrs)

HORMAD1 emerges as a potential target in triple‑negative breast cancer (43 hrs)

more #pharmaceuticals

Biotech

Atezolizumab added to chemoradiation fails to improve limited‑stage SCLC survival (18 hrs)

HORMAD1 emerges as a potential target in triple‑negative breast cancer (43 hrs)

Alfasigma pays $300M to GSK for linerixibat rights, expanding liver-disease portfolio (46 hrs)

StackHealth Time Machine

NorthFeed Inc.

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.